November recorded the third highest number of Special Access Scheme approvals of the year, latest figures have shown.
A total of 11,430 medicinal cannabis approvals were signed off by the Therapeutic Goods Administration (TGA), a number only eclipsed in 2022 in March and May.
It takes the total for the first 11 months of the year to 110,850. In the 2021 calendar year the TGA issued 122,480 approvals.
Meanwhile, the number of applications lodged through the Authorised Prescriber scheme in November nudged just above 1,000.
Last month’s SAS-B total included 9,322 schedule 8 approvals, 82% of the total, with schedule 4 medications making up the balance.
Oral liquid captured 52% of the market with flower at 37%.
In line with previous trends, 45% of approvals were for chronic pain, 31% for anxiety and 6.6% for sleep disorder.
